New and existing tools, including cPET, cARIA, and the Dementia Differential Analysis report, extend Combinostics’ solution beyond neurological image quantification and support end-to-end workflows.
Fountain Health announces 100 percent coverage of Combinostics cMRI and cDSI. The company is now the first and only health insurance platform to provide complete coverage for the AI-enabled neurological imaging and decision support solutions.
Dr. Erik Post and Dr. Hans-Peter Huber have joined Combinostics as Group Chief Financial Officer (CFO) and Vice President of European Sales, respectively. Their contributions include considerable experience scaling software solutions.
cNeuro® cDSI™ and cNeuro cMRI™ achieve EC-certification under MDR, ensuring continued delivery of services to European customers.
The latest version of cNeuro® includes the launch of the Dementia Differential Analysis report, new disease-specific reports, additional automated MRI quantifications and imaging biomarkers, and more.
Our industry-first Dementia Differential Analysis report is based on MRI data only and compares the patient’s data against reference data from thousands of previous patients.
Tom Gardner has joined Combinostics as the Vice President of US Sales. He has over 25 years of experience successfully developing and leading sales teams in the AI and clinical imaging software solutions space.
Combinostics has been selected by the jury to progress to the finals for the neurotechprize run by EIT Health and Biogen. The award recognizes technological innovations for the diagnosis and care of Alzheimer’s patients.
We are confident that Combinostics is not affected by the recent vulnerabilities found in Apache Log4j. We will continue to track updates relating to this vulnerability.
Combinostics will demonstrate the features of cNeuro® 2.0, the latest release to their AI-based suite of products, and applications under development at RSNA 2021.